



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22572/S-004

SUPPLEMENT APPROVAL

Mobius Therapeutics
Attention: Alan Beckman
Director of RA/QA
1000 Executive Parkway, Suite 224
St. Louis, MO 63141

Dear Mr. Beckman:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 20, 2015, and your amendments, submitted under to section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mitosol (mitomycin for solution).

This Prior Approval supplemental new drug application proposes:

- To change the kit manufacturing facility to (b) (4)
- Change the kit (b) (4) facility to (b) (4).
- Elimination of the alcohol prep pad from the kit contents and revise the labeling to reflect the elimination of the alcohol prep pad.
- Change to a smaller outer tray and corrugated shipping carton
- Incorporation of a new protective foam pouch to contain the drug vial

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the Instructions for Use, outer tray label), with the addition of any labeling changes in pending

“Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. June Germain, Safety Regulatory Project Manager, at (301) 796-4024.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, MD
Deputy Director
Division of Transplant and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURES: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WILEY A CHAMBERS
01/20/2016